Orbital Therapeutics is focused on advancing the potential of RNA medicines through a technology-agnostic approach that allows for precise design tailored to the biology of various diseases. Their innovative platform integrates a comprehensive range of state-of-the-art technologies, enabling the calibration of expression, duration, and tissue distribution of RNA medicines. This flexibility allows Orbital to create RNA therapies that are specifically engineered to address the complexities of different diseases, enhancing the effectiveness of treatments by ensuring that the right proteins are expressed in the appropriate cells and tissues.

The company’s pipeline includes a diverse array of RNA medicine programs targeting immunomodulation for autoimmune diseases and oncology, next-generation vaccines, and protein therapeutics. Orbital is developing advanced mRNA vaccines that go beyond existing solutions, incorporating strategies such as heterologous prime-boost and combination vaccines to improve efficacy. Additionally, they are exploring the use of RNA to deliver protein therapeutics, addressing challenges related to expression duration, delivery, and the complexity of the proteins involved. By leveraging technologies such as linear and circular mRNA, lipid nanoparticles, virus-like particles, and machine learning, Orbital Therapeutics aims to revolutionize the landscape of RNA-based therapies.

United States

Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans.

Orbital Therapeutics

Company Details